Hemophilia carrier's awareness, diagnosis, and management in emerging countries: a cross-sectional study in Côte d'Ivoire (Ivory Coast).


Journal

Orphanet journal of rare diseases
ISSN: 1750-1172
Titre abrégé: Orphanet J Rare Dis
Pays: England
ID NLM: 101266602

Informations de publication

Date de publication:
01 02 2019
Historique:
received: 08 09 2018
accepted: 21 01 2019
entrez: 3 2 2019
pubmed: 3 2 2019
medline: 20 4 2019
Statut: epublish

Résumé

Little data is available on awareness of hemophilia carrier condition or associated bleeding risk and management in Sub-Saharan African countries. This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results. Another purpose was to provide Ivorian hemophilia carriers with counseling on their risk of bleeding and of having children with hemophilia. A 12-month prospective study was conducted involving Ivorian hemophilia carriers recruited trough pedigree analysis pertaining to 81 hemophilia patients followed-up at the Yopougon Hemophilia Treatment Center in Abidjan. They were assessed using in-depth interviews, pedigree analysis, and laboratory testing. Sixty-one subjects comprising 27 obligate and 34 possible carriers were recruited. None had previously been assessed, with 64% unaware of their carrier status despite a familial history of hemophilia in 69%. The most frequently reported bleeding symptom was menorrhagia (31%). Prolonged bleeding was reported after vaginal delivery in 19.6%, post-surgery in 4.9%, and post-dental extraction in 4.9%. Only one carrier was treated with tranexamic acid, with no other hemostatic therapy recorded. The median (range) clotting FVIII was 0.85 IU/mL (0.24-1.90 IU/mL) and FIX 0.60 IU/mL (0.42-1.76 IU/mL) in hemophilia A and B carriers, respectively. HA carriers had a FVIII < 0.5 IU/mL in 12.5%. This study highlights the need of implementing care for hemophilia carriers in developing countries, and the high value of pedigree analysis for carrier identification, along with the relevance of diagnosis, treatment, and education of carriers, families, and caregivers.

Sections du résumé

BACKGROUND
Little data is available on awareness of hemophilia carrier condition or associated bleeding risk and management in Sub-Saharan African countries. This study sought to identify hemophilia carriers in Côte d'Ivoire in order to collect data on demographics, bleeding phenotype, and laboratory results. Another purpose was to provide Ivorian hemophilia carriers with counseling on their risk of bleeding and of having children with hemophilia. A 12-month prospective study was conducted involving Ivorian hemophilia carriers recruited trough pedigree analysis pertaining to 81 hemophilia patients followed-up at the Yopougon Hemophilia Treatment Center in Abidjan. They were assessed using in-depth interviews, pedigree analysis, and laboratory testing.
RESULTS
Sixty-one subjects comprising 27 obligate and 34 possible carriers were recruited. None had previously been assessed, with 64% unaware of their carrier status despite a familial history of hemophilia in 69%. The most frequently reported bleeding symptom was menorrhagia (31%). Prolonged bleeding was reported after vaginal delivery in 19.6%, post-surgery in 4.9%, and post-dental extraction in 4.9%. Only one carrier was treated with tranexamic acid, with no other hemostatic therapy recorded. The median (range) clotting FVIII was 0.85 IU/mL (0.24-1.90 IU/mL) and FIX 0.60 IU/mL (0.42-1.76 IU/mL) in hemophilia A and B carriers, respectively. HA carriers had a FVIII < 0.5 IU/mL in 12.5%.
CONCLUSIONS
This study highlights the need of implementing care for hemophilia carriers in developing countries, and the high value of pedigree analysis for carrier identification, along with the relevance of diagnosis, treatment, and education of carriers, families, and caregivers.

Identifiants

pubmed: 30709356
doi: 10.1186/s13023-019-1005-9
pii: 10.1186/s13023-019-1005-9
pmc: PMC6359866
doi:

Substances chimiques

Tranexamic Acid 6T84R30KC1
Factor VIII 9001-27-8

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

26

Références

Haemophilia. 2011 Mar;17(2):246-51
pubmed: 21118332
J Genet Couns. 2015 Dec;24(6):978-86
pubmed: 25828422
Am J Hum Genet. 1962 Jun;14:135-48
pubmed: 14467629
Haemophilia. 2018 May;24 Suppl 6:29-36
pubmed: 29878651
Haemophilia. 2017 May;23(3):e225-e227
pubmed: 28306216
Blood. 1987 May;69(5):1539-41
pubmed: 2882794
Br J Haematol. 1997 Jun;97(3):558-60
pubmed: 9207400
Haemophilia. 2010 Jan;16(1):20-32
pubmed: 19845775
BMC Hematol. 2017 Apr 24;17:8
pubmed: 28451435
Haemophilia. 1998 Jul;4(4):341-5
pubmed: 9873752
Br J Haematol. 1975 Aug;30(4):447-56
pubmed: 1103952
Haemophilia. 2002 Jan;8(1):51-5
pubmed: 11886465
N Engl J Med. 2001 Jun 7;344(23):1773-9
pubmed: 11396445
Blood Coagul Fibrinolysis. 2017 Dec;28(8):642-645
pubmed: 28731872
Br J Haematol. 2015 Jul;170(2):223-8
pubmed: 25832012
Blood. 2006 Jul 1;108(1):52-6
pubmed: 16551972
Haemophilia. 2004 Sep;10(5):560-4
pubmed: 15357784
Haemophilia. 2008 Jul;14 Suppl 3:181-7
pubmed: 18510540
Haemophilia. 2010 Jan;16(1):111-7
pubmed: 19758307
Haemophilia. 2002 Sep;8(5):680-4
pubmed: 12199679
Ann Hematol. 1992 Jan;64(1):2-11
pubmed: 1739755

Auteurs

Catherine Lambert (C)

Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium. Catherine.lambert@uclouvain.be.

N' Dogomo Meité (ND)

Division of Clinical Hematology, Centre Hospitalier universitaire de Yopougon, Abidjan, Côte d'Ivoire.

Ibrahima Sanogo (I)

Division of Clinical Hematology, Centre Hospitalier universitaire de Yopougon, Abidjan, Côte d'Ivoire.

Sébastien Lobet (S)

Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Division of Physical Medicine and Rehabilitation, Cliniques universitaires Saint-Luc, Brussels, Belgium.
Université catholique de Louvain, Secteur des Sciences de la Santé, Institut de Recherche Expérimentale et Clinique, Neuromusculoskeletal Lab, Brussels, Belgium.

Eusèbe Adjambri (E)

Hematology unit of the Central Laboratory, Centre Hospitalier universitaire de Yopougon, Abidjan, Côte d'Ivoire.

Stéphane Eeckhoudt (S)

Hemostasis and Thrombosis Laboratory, Division of Biological Chemistry, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Cedric Hermans (C)

Hemostasis and Thrombosis Unit, Division of Hematology, Cliniques universitaires Saint-Luc, Brussels, Belgium.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH